3-Year Framework for Exchange of Non-Public Information

The U.S. Securities and Exchange Commission (SEC) and the U.S. Food and Drug Administration (FDA) have signed a Memorandum of Understanding (MOU) effective until August 31, 2026, for a three-year period. The agreement establishes a system for mutual exchange of information regarding FDA-regulated products and their manufacturers, distributors, and sellers, including the establishment of dedicated liaisons and secure transmission channels. The SEC can now use non-public information received from the FDA in the review of public company disclosures, enforcement investigations, and litigation. The key point is that this is not just a cooperation declaration but an operational framework enabling direct cross-verification of clinical trial and approval information with investor disclosures.

Enhanced Cross-Verification of Clinical and Approval Disclosures

Biopharma companies must now manage their external communications regarding clinical stages, safety signals, FDA meeting outcomes, and approval likelihood with greater scrutiny. With the SEC's Enforcement and Corporate Finance divisions now linked to the FDA's Office of Chief Counsel, disclosure language can be swiftly verified against data submitted to the FDA or feedback from regulatory agencies. In 2025, the SEC filed a lawsuit against former executives of Allarity Therapeutics (ALLR) for allegedly concealing insufficient data on the multi-kinase inhibitor dovitinib and the FDA's recommendation for a new Phase 3 trial from investors. This system is designed to detect discrepancies between regulatory feedback and securities disclosures at an earlier stage.

Impact on Pre-Approval Trading and Shadow Trading

FDA information can significantly move stock prices before clinical halts, key results, or NDA approval decisions, creating high incentives for insider trading. In the 2011 FDA employee case, trades were made using information about the approval of vilazodone hydrochloride (Viibryd), a serotonin transporter inhibitor and 5-HT1A partial agonist. In 2024, a jury found Matthew Panuett guilty of using confidential information about Pfizer's (PFE) acquisition of Medivation to trade options in competitor Incyte (INCY), generating over $100,000 in shadow trading profits. As a result, the surveillance scope now extends beyond the stock of the developing company to competitors, options, and event prediction markets.

Implications for the $18.4 Billion Biopharma Stock Market

As of September 2026, the Nasdaq Biotechnology Index (NBI) includes 263 stocks with a combined market capitalization of $18.4 billion, making fair distribution of regulatory information directly tied to market trust. The MOU does not alter FDA approval processes or clinical stages, nor does it target specific drugs, indications, or competitive pipelines. Instead, it increases the burden of integrated management of pre-disclosure clinical data access rights, FDA meeting minutes, submission documents, and disclosure approval procedures. Information barriers between R&D teams and investor relations/legal teams, employee trading restrictions, and data room access records are emerging as key controls for corporate value protection.